Genticel SA

DUBLIN, June 8, 2022 /PRNewswire/ -- The "Global Precision Medicine Partnering Terms and Agreements 2015-2022" report has been added to ResearchAndMarkets.com's offering. The Global Precision Medicine Partnering Terms and Agreements 2015-2022 report provides comprehensive access to available deals and contract documents for over 1,900 Precision Medicine deals. The report takes the reader through a comprehensive review Precision Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Precision Medicine partnering deals. The report presents financial deal term values for Precision Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the Precision Medicine partnering field; both the leading deal values and most active Precision Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market. One of the key highlights of the report is that over 1,900 online deal records of actual Precision Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. A comprehensive series of appendices is provided organized by Precision Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand. The report also includes numerous tables and figures that illustrate the trends and activities in Precision Medicine partnering and dealmaking since 2015. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Precision Medicine technologies and products. Global Precision Medicine Partnering Terms and Agreements 2015-2022 provides the reader with the following key benefits: In-depth understanding of Precision Medicine deal trends since 2015 Access to headline, upfront, milestone and royalty data Detailed access to actual Precision Medicine contracts entered into by leading biopharma companies Identify most active Precision Medicine dealmakers since 2015 Insight into terms included in a Precision Medicine partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type Analyzing actual contract agreements allows assessment of the following: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive Summary Chapter 1 - Introduction Chapter 2 - Trends in Precision Medicine dealmaking 2.1. Introduction 2.2. Precision Medicine partnering over the years 2.3. Most active Precision Medicine dealmakers 2.4. Precision Medicine partnering by deal type 2.5. Precision Medicine partnering by therapy area 2.6. Deal terms for Precision Medicine partnering 2.6.1 Precision Medicine partnering headline values 2.6.2 Precision Medicine deal upfront payments 2.6.3 Precision Medicine deal milestone payments 2.6.4 Precision Medicine royalty rates Chapter 3 - Leading Precision Medicine deals 3.1. Introduction 3.2. Top Precision Medicine deals by value Chapter 4 - Most active Precision Medicine dealmakers 4.1. Introduction 4.2. Most active Precision Medicine dealmakers 4.3. Most active Precision Medicine partnering company profiles Chapter 5 - Precision Medicine contracts dealmaking directory 5.1. Introduction 5.2. Precision Medicine contracts dealmaking directory Chapter 6 - Precision Medicine dealmaking by technology type Appendices Appendix 1 - Precision Medicine deals by company A-Z Appendix 2 - Precision Medicine deals by stage of development Appendix 3 - Precision Medicine deals by deal type Appendix 4 - Precision Medicine deals by therapy area Appendix 5 - Deal type definitions Appendix 6 - Further reading on dealmaking Companies Mentioned Microbiotica Mitsubishi Tanabe Pharma HMNC Brain Health Clearbridge Biomedics Sunnybrook Health Sciences Centre Unilabs Pittsburgh Life Sciences Greenhouse AmpTec Evotec GenVec Nordic Bioscience Cystic Fibrosis Foundation Fabric Genomics Cyclica Clinica Ruiz Critical Diagnostics Clinical Genomics Clinical Outcomes Tracking and Analysis American Association for Cancer Research American Association of Neuromuscular & Electrodiagnostic Medicine American Diabetes Association Lung Cancer Alliance Covance Valence Discovery Science Foundation Ireland Advanced Cell Diagnostics Advanced Nuclear Medicine Ingredients Genticel HiberCell ReproCell Fibrocell Science ZERO Childhood Cancer Rady Children's Institute for Genomic Medicine West China Hospital Massachusetts General Hospital Massachusetts Institute of Technology Massachusetts Life Sciences Center Fundacion Progreso y Salud 2bPrecise Mayo Clinic For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 SOURCE Research and Markets